Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 16/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.35 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958066 | 1.00 | KLKB1 (0.36) | KLKB1METTL3EEDRBBP4SUZ12 | |
| SCHEMBL29174288 | 0.91 | KLKB1 (0.38) | KLKB1METTL3 | |
| SCHEMBL29957965 | 0.85 | KLKB1 (0.36) | KLKB1METTL3 | |
| SCHEMBL27033970 | 0.85 | KLKB1 (0.36) | KLKB1METTL3 | |
| SCHEMBL27033983 | 0.84 | KLKB1 (0.37) | KLKB1METTL3 | |
| SCHEMBL29958146 | 0.84 | KLKB1 (0.37) | KLKB1METTL3 | |
| SCHEMBL27033856 | 0.84 | KLKB1 (0.35) | KLKB1METTL3 | |
| SCHEMBL29958373 | 0.84 | KLKB1 (0.35) | KLKB1METTL3 | |
| SCHEMBL29958191 | 0.81 | KLKB1 (0.38) | KLKB1METTL3 | |
| SCHEMBL27033449 | 0.81 | KLKB1 (0.38) | KLKB1METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885METTL3 4613/4885EED 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.